What Кларитромицин-OBL Treats: Main Uses and Benefits

Кларитромицин-OBL (Clarithromycin) is used across multiple therapeutic domains, primarily to manage symptoms related to susceptible bacterial infections. Its use is considered relevant for easing symptoms associated with bacterial illness in various body systems, applicable within clinical settings that involve acute or disruptive symptom patterns. In clinical practice, the medication is used to help manage acute episodes of sinusitis, tonsillitis, and pneumonia, as well as certain uncomplicated skin infections (e.g., cellulitis) and specific systemic challenges.

It is relevant for managing symptoms that interfere with daily comfort, providing supportive relief that generally helps patients cope more steadily with difficult acute episodes. This includes its key role in combination regimens used to address conditions linked to H. pylori associated with duodenal ulcers. This treatment is applied across domains where additional symptomatic support is needed, assisting with maintaining functional stability when symptoms become more noticeable. It helps address symptom clusters such as sore throat, cough, and localized pain/tenderness, contributing to easing the overall symptom load during symptomatic periods.

---

Therapeutic Context: Symptom Management Кларитромицин-OBL is used to help manage symptoms related to inflammation, pain, and systemic discomfort that arise from susceptible bacterial infections in the respiratory tract and skin.

---

Regulatory References

1. U.S. Food and Drug Administration (FDA) Drug Label

Clarithromycin-OBL is generally used to treat bacterial infections in most adults and children aged 6 months and older. Your doctor will determine if it is appropriate for your specific condition.

---

Contraindications (Who Cannot Use)

This medication should not be used if you have:

• A known allergy to clarithromycin or any other macrolide antibiotic (like erythromycin or azithromycin).
• A history of QT prolongation (a type of heart rhythm disorder) or certain ventricular arrhythmias, including torsades de pointes.
• Severely decreased potassium or magnesium levels in your blood (hypokalemia or hypomagnesemia).
• A history of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use.
• Severe hepatic failure combined with renal impairment.
• Concomitant use of certain medications, which is strictly contraindicated due to the risk of serious side effects. These include: cisapride, pimozide, ergotamine, dihydroergotamine, colchicine (in patients with kidney or liver problems), and certain statins like simvastatin and lovastatin.

---

Use in Specific Populations

Population	Key Consideration
Pregnancy	Use is generally avoided unless the benefits clearly outweigh the risks, especially during the first trimester, due to potential harm shown in animal studies and conflicting human data.
Breastfeeding	Clarithromycin passes into breast milk. Use with caution; monitor the infant for gastrointestinal disturbances.
Renal Impairment	Dosage adjustment is necessary for patients with severe kidney problems.
Myasthenia Gravis	May worsen symptoms of this muscle-weakening condition. Use with caution.

Кларитромицин-OBL (Clarithromycin) is a potent inhibitor of the CYP3A4 enzyme, a system in the liver and gut responsible for metabolizing many other medicines. This inhibition can significantly increase the blood levels of co-administered drugs, leading to serious or life-threatening toxicities. Due to this risk, certain combinations are strictly contraindicated.

Contraindicated Combinations

Co-administration is prohibited with drugs that can cause QT prolongation or serious cardiac arrhythmias, such as Pimozide, Cisapride, Ivabradine, and others. The risk of life-threatening events, including Torsades de pointes, is significantly increased.

It is also contraindicated with HMG-CoA reductase inhibitors (Statins) that are heavily metabolized by CYP3A4, specifically Lovastatin and Simvastatin, due to the high risk of myopathy, including rhabdomyolysis. Concomitant use with Ergot Alkaloids (Ergotamine, Dihydroergotamine) is prohibited because of the potential for acute ergot toxicity, characterized by vasospasm and ischemia. The combination with Colchicine is also contraindicated, especially in patients with existing kidney or liver impairment, due to elevated risk of Colchicine toxicity.

Use with Caution

Many other medications require caution and careful monitoring, including oral anticoagulants, certain benzodiazepines, and other CYP3A4 substrates. Dose adjustments or the use of alternative medicines may be necessary to safely manage the interaction risk.

Blocking Bacterial Protein Synthesis

Clarithromycin acts as a specific inhibitor by targeting the 50S ribosomal subunit inside susceptible bacteria, binding to the 23S ribosomal RNA . This molecular interaction physically blocks the Nascent Peptide Exit Tunnel, thereby preventing the elongation of polypeptide chains. The resulting failure to synthesize essential structural and functional proteins immediately halts the bacteria's ability to grow and divide (a bacteriostatic effect), which results in the cessation of bacterial growth and replication.

Mechanistic Enhancement by Active Metabolite

The body converts Clarithromycin into an active component, 14-hydroxyclarithromycin, which maintains the identical mechanism of action, binding to the same ribosomal target. This conversion leads to a synergistic inhibitory activity on protein synthesis where both the parent drug and the metabolite simultaneously suppress bacterial growth. The combined activity of the two compounds contributes to the drug's systemic distribution and ribosomal blockade, which facilitates a reduction in the overall microbial load by the host's immune system.

Constraints on Ribosomal Targeting

The drug's activity is strictly dependent on the integrity of the ribosomal binding site; its mechanism is fully inoperative against viruses or fungi. Functional activity is lost when bacteria develop resistance mechanisms, typically through gene mutations that modify the 23S rRNA binding pocket or by activating efflux pumps that actively expel the drug from the cell. These constraints define the necessary boundaries for the drug's observed physiological function.

Кларитромицин-OBL is administered via the oral route, with the usage schedule and administration conditions dependent on the specific formulation. Immediate-release (IR) tablets and the oral suspension are typically taken in doses ranging from 250 mg to 500 mg and are scheduled for administration every 12 hours (twice daily). These IR forms may be ingested with or without food.

In contrast, the extended-release (ER) tablets are generally taken as a 1000 mg total daily dose once every 24 hours and must be taken with food to align with labeled usage parameters. The ER formulation carries a specific procedural constraint: the tablet must be swallowed whole and is officially restricted from being crushed, cut, or chewed. For pediatric patients (6 months to 12 years), dosing is determined based on body weight, using a formula of 15 mg/ kg/ day divided into two daily doses.

Treatment duration for most infections is fixed, typically spanning 7 to 14 days. Dosage adjustments are officially required for certain patient subsets; adults with severe renal impairment (CLcr < 30 mL/ min) must receive a total dose that is typically reduced by 50%, and the duration for this group is restricted to a maximum of 14 days.

Research Evidence / Overview of Studies for Кларитромицин-OBL

Research focusing on Кларитромицин-OBL (Clarithromycin) utilizes evidence primarily from controlled clinical trials, including Randomized Controlled Trials (RCTs) and systematic reviews (meta-analyses), across its key areas of use. This summary provides an outline of what the studies examined and where uncertainties remain, using language intended to describe the evidence without making clinical claims.

---

Evidence Structure for Respiratory Tract Infections

Research focusing on Clarithromycin was studied for conditions such as pneumonia, acute bacterial sinusitis, and tonsillitis through Randomized Controlled Trials (RCTs). The trials monitored outcomes related to physical discomfort and outcomes describing episodic or acute changes. Researchers monitored endpoints such as Clinical Cure Rates and used Clinical Symptom Scores (CSS) to track the measured changes in symptoms. Furthermore, studies monitored the Bacteriological Eradication Rate—research described the measured absence or presence of the targeted susceptible organism.

Research highlights changes measured during the study period, typically focusing on observations within the treatment window (usually 5 to 14 days) and immediate post-treatment assessments. However, the evidence is limited in terms of providing long-term data; long-term effects are not fully established regarding the evolution of symptoms over several months or years.

---

Evidence Structure for H. pylori and Duodenal Ulcers

Clarithromycin was evaluated in studies as a crucial component of multi-drug combination regimens for managing conditions associated with H. pylori infection linked to duodenal ulcers. The primary focus of this research was to monitor the H. pylori Eradication Success Rate—the proportion of patients in whom the bacteria were no longer detectable. This evidence contributes to understanding symptom patterns, particularly concerning the monitoring of complications such as ulcer relapse.

A major gap acknowledged is the increasing rate of resistance to Clarithromycin observed in H. pylori strains. This resistance was observed in some studies to be associated with findings were mixed when comparing outcomes to alternative protocols. Therefore, evidence quality varies across studies concerning performance without regional consideration.

Key Studies & References Clarithromycin Tablets, USP (DailyMed Drug Label)

Common questions about Кларитромицин-OBL (FAQ)

Q: Can I take the extended-release tablet with or without food?

A: According to the official product information, the extended-release tablet formulation must be taken with food. This is a requirement in the official instructions to align with how the medication was studied and approved.

---

Q: Do I need a prescription to get Clarithromycin-OBL?

A: Yes, Clarithromycin-OBL is classified as a prescription-only medication. It is an antibiotic that requires authorization from a licensed healthcare provider.

---

Q: What are the most serious side effects I should watch out for?

A: Serious adverse reactions documented in regulatory sources include potential liver problems (hepatitis) and severe, rare skin reactions (like Stevens-Johnson Syndrome). There is also a risk of rare heart rhythm disorders, specifically QT prolongation, which may lead to life-threatening arrhythmias. It is important to review these potential serious risks listed in the official warnings.

---

Q: What should I do if I forget to take a dose of Clarithromycin-OBL?

A: If a dose is missed, regulatory guidance suggests taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, regulatory guidance suggests skipping the missed dose and continuing with the next scheduled dose. Official instructions caution against taking extra medicine to compensate for a missed dose.

---

Q: Is Clarithromycin-OBL safe to use during pregnancy?

A: Official labeling advises that Clarithromycin should generally not be used during pregnancy, particularly during the first trimester, due to findings in animal studies. Its use is generally restricted unless an official medical assessment determines the potential benefit outweighs the risk, and an appropriate alternative is unavailable.

---

Q: Does Clarithromycin-OBL treat all kinds of infections, like viruses or fungal infections?

A: No, this medication is a macrolide antibiotic, meaning it is specifically intended to work against susceptible bacterial infections. According to regulatory information, it is not effective against infections caused by viruses, such as the common cold or flu, or against fungal infections.

---

Q: What if I take too much Clarithromycin-OBL (overdose)?

A: In the event of an overdose, regulatory documents note that symptoms often involve gastrointestinal effects, such as abdominal pain, vomiting, and nausea. Official labeling advises that in the event of a suspected overdose, contact with a poison control center or seeking immediate medical attention is necessary.

How to Store and Dispose of Clarithromycin

Official regulatory information requires strict adherence to specific storage and disposal protocols to maintain the drug's effectiveness and ensure safety.

Storage Requirements

Storage Component	Requirement (Official Labeling)
Temperature	Store tablets at controlled room temperature, 68 F to 77 F (20 C to 25 C).
Environment	Keep tablets protected from excess heat, light, and moisture.
Suspension (Liquid)	The constituted oral suspension must not be refrigerated and must be used within 14 days of mixing.
Protection	Keep all forms of the medicine in the original, tightly closed container and out of the reach of children.

Disposal Instructions

Do not flush unused or expired clarithromycin down the toilet or pour it down a drain. Follow official national guidelines, such as FDA recommendations or local take-back programs, for the safe disposal of pharmaceutical waste.